Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

@article{Punglia2008PharmacogenomicVO,
  title={Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.},
  author={Rinaa S Punglia and Harold J. Burstein and Eric P. Winer and Jane C. Weeks},
  journal={Journal of the National Cancer Institute},
  year={2008},
  volume={100 9},
  pages={642-8}
}
BACKGROUND Adjuvant endocrine treatment with aromatase inhibitors improves disease-free survival compared with tamoxifen in postmenopausal women with estrogen receptor-positive breast cancer. This difference could be due to differences in tamoxifen metabolism because levels of endoxifen, the active tamoxifen metabolite, vary with the number of mutant alleles, including the *4 allele, of the gene encoding cytochrome P450 2D6 (CYP2D6). METHODS We created a Markov model to determine whether… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Breast cancer treatment outcome with adjuvant tamoxifen in relation to patient CYP 2 D 6 and CYP 2 C 19 genotypes

  • MP Goetz, SK Knox, VJ Suman
  • J Clin Oncol
  • 2007

The impact of cytochrome P 450 2 D 6 metabolism in women receiving adjuvant tamoxifen

  • Z Desta, BA Ward, NV Soukhova, DA Flockhart
  • Breast Cancer Res Treat
  • 2007

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 - year survival : an overview of the randomised trials

  • AS Coates, A Keshaviah, B Thurlimann
  • Lancet
  • 2005

Similar Papers

Loading similar papers…